SOURCE: Virtual Radiologic

Virtual Radiologic

September 20, 2013 10:00 ET

Virtual Radiologic Expands Intellectual Property Complaint Against Tandem Radiology, Direct Radiology and Imaging Advantage

vRad Alleges Infringement of Additional, Newly Issued Patent

MINNEAPOLIS, MN--(Marketwired - Sep 20, 2013) -  Virtual Radiologic (vRad), a technology-enabled national radiology practice and the world's largest telemedicine company, and its subsidiary, NightHawk Radiology Services (NRS), have amended their complaint in their previously filed lawsuit against Imaging Advantage, Direct Radiology, and Tandem Radiology and certain of Tandem's employees and founders to allege infringement of an additional, recently issued patent (No. 8,515,778). The amended Complaint was filed on Sept. 12, 2013, in the United States District Court for the District of Arizona.

The previously announced lawsuit alleges copyright infringement and misappropriation of trade secrets by Tandem Radiology, and claims infringement of patent rights by Tandem and its customers, Direct Radiology and Imaging Advantage, through their use of Tandem's platform. Following the amendment, the lawsuit now alleges that the defendants directly infringe upon five of vRad's 11 issued patents: U.S. Patent Numbers 7,970,634, 8,090,593, 8,145,503, 8,195,481 and 8,515,778. The lawsuit seeks to stop the defendants from marketing, selling and using infringing systems, as well as monetary damages, among other relief.

About vRad
Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology's pivotal role in patient care. vRad's more than 400 radiologists serve over 2,000 facilities, reading more than 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment. For more information, visit For real-time updates, follow us on Twitter (@vRad), or "like" us on Facebook.

Contact Information